Scinai Immunotherapeutics Ltd.
SCNIHealthcare|Biotechnology|IL
$0.44
-0.01 (-2.22%)
DCF Value
$98.25
Tangible Book / Share
$0.21
Cash / Share
$0.05
Financials
Financial Snapshot
Market Cap
$228.0K
Enterprise Value
$955.0K
Revenue (TTM)
$1.5M
Net Income (TTM)
-$2.6M
Cash & Investments
$2.9M
Net Cash
-$727.0K
Free Cash Flow (TTM)
-$7.5M
Operating CF (TTM)
-$7.4M
Debt/Equity
0.31
Cash Runway & Burn Rate
Cash on Hand
$2.9M
Quarterly Burn
$1.9M
Monthly Burn
$616.9K
Est. Runway
~1.5 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $6.6M | $20.5M | $20.3M | $21.0M | $2.9M | $17.4M | $14.1M | $4.9M | $2.0M | $1.7M | $2.9M | |
| Operating Cash Flow | -$2.5M | -$2.9M | -$15.3M | -$22.3M | -$21.1M | -$7.4M | -$7.3M | -$9.4M | -$6.3M | -$6.0M | -$7.4M | |
| Free Cash Flow | -$2.5M | -$4.2M | -$21.6M | -$24.5M | -$22.9M | -$7.6M | -$8.1M | -$10.0M | -$6.3M | -$6.1M | -$7.5M | |
| Capital Expenditure | -$5.2K | -$1.3M | -$6.3M | -$2.2M | -$1.8M | -$139.0K | -$836.0K | -$637.0K | -$12.0K | -$24.0K | -$127.8K | |
| Financing Cash Flow | $0.00 | $17.8M | $22.5M | $24.7M | $4.0M | $21.4M | $6.8M | $1.1M | $3.4M | $5.8M | $6.5M |
R&D Spending
R&D (TTM)
$2.0M
R&D Intensity
132.1%
R&D Growth vs Prior
-16.7%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $658.0K | $1.3M | $1.5M | |
| R&D Expense | $2.4M | $5.6M | $19.3M | $19.9M | $14.4M | $2.6M | $5.8M | $5.2M | $5.5M | $2.4M | $2.0M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | 840.7% | 180.7% | 132.1% | |
| SG&A | $1.1M | $1.4M | $1.4M | $2.8M | $4.7M | $7.4M | $5.3M | $4.5M | $2.5M | $2.5M | $2.7M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $658.0K | $1.3M | $1.5M | |
| Cost of Revenue | $0.00 | $123.6K | $72.3K | $461.7K | $708.9K | $747.6K | $0.00 | $0.00 | $1.2M | $4.0M | $5.3M | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | -$708.9K | -$747.6K | $0.00 | $0.00 | -$580.0K | -$2.7M | -$3.8M | |
| R&D | $2.4M | $5.6M | $19.3M | $19.9M | $14.4M | $2.6M | $5.8M | $5.2M | $5.5M | $2.4M | $2.0M | |
| SG&A | $1.1M | $1.4M | $1.4M | $2.8M | $4.7M | $7.4M | $5.3M | $4.5M | $2.5M | $2.5M | $2.7M | |
| Operating Income | -$3.1M | -$6.8M | -$20.6M | -$22.7M | -$19.8M | -$10.8M | -$11.1M | -$9.7M | -$8.6M | -$7.5M | -$8.4M | |
| Interest Expense | $100.00 | $20.5K | $3.8M | $4.3M | $338.8K | $3.4M | $0.00 | $3.8M | $1.4M | $359.0K | $215.4K | |
| Pretax Income | -$2.4M | -$9.9M | -$23.5M | -$31.6M | -$1.3M | -$12.4M | -$5.8M | -$6.5M | $4.8M | -$8.3M | -$2.6M | |
| Net Income | -$2.4M | -$9.9M | -$23.5M | -$31.6M | -$1.3M | -$12.4M | -$5.8M | -$6.5M | $4.8M | -$8.3M | -$2.6M | |
| EPS (Diluted) | -2823200.00 | -7902800.00 | -14358000.00 | -15488000.00 | -467560.00 | -3507480.00 | -160000.00 | -64000.00 | 60.00 | -36.00 | -62161.60 | |
| EBITDA | -$2.9M | -$6.7M | -$20.5M | -$22.2M | -$19.1M | -$10.3M | -$5.2M | -$2.2M | -$7.0M | -$6.5M | -$6.7M | |
| Shares Out. (M) | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.23 | 57.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.1M | $20.5M | $20.3M | $21.0M | $2.9M | $17.4M | $14.1M | $4.9M | $2.0M | $1.7M | $2.9M | |
| Short-Term Investments | $2.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $6.8M | $21.6M | $20.5M | $21.2M | $3.3M | $17.8M | $14.4M | $5.4M | $2.4M | $2.1M | $3.5M | |
| Total Assets | $7.8M | $23.5M | $28.3M | $33.5M | $17.7M | $32.0M | $27.1M | $17.5M | $13.4M | $11.6M | $17.2M | |
| Total Current Liabilities | $356.9K | $2.0M | $5.8M | $5.5M | $20.0M | $2.4M | $2.3M | $1.8M | $1.8M | $1.6M | $2.2M | |
| Long-Term Debt | $0.00 | $0.00 | $25.2M | $35.8M | $0.00 | $27.2M | $20.1M | $19.4M | $260.0K | $294.0K | $285.0K | |
| Total Liabilities | $1.2M | $7.3M | $36.6M | $52.4M | $22.2M | $31.1M | $28.8M | $22.0M | $3.5M | $3.5M | $5.4M | |
| Stockholders' Equity | $6.6M | $16.2M | -$8.3M | -$18.8M | -$4.5M | $982.0K | -$1.8M | -$4.6M | $10.0M | $8.1M | $11.7M | |
| Retained Earnings | -$23.1M | -$35.5M | -$56.5M | -$92.8M | -$101.1M | -$110.0M | -$115.8M | -$122.3M | -$117.5M | -$125.8M | -$124.3M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.5M | -$2.9M | -$15.3M | -$22.3M | -$21.1M | -$7.4M | -$7.3M | -$9.4M | -$6.3M | -$6.0M | -$7.4M | |
| Capital Expenditure | -$5.2K | -$1.3M | -$6.3M | -$2.2M | -$1.8M | -$139.0K | -$836.0K | -$637.0K | -$12.0K | -$24.0K | -$127.8K | |
| Free Cash Flow | -$2.5M | -$4.2M | -$21.6M | -$24.5M | -$22.9M | -$7.6M | -$8.1M | -$10.0M | -$6.3M | -$6.1M | -$7.5M | |
| Investing Cash Flow | -$2.0M | $1.9M | -$6.3M | -$2.1M | -$1.7M | -$139.0K | -$836.0K | -$637.0K | -$12.0K | -$24.0K | $2.6M | |
| Financing Cash Flow | $0.00 | $17.8M | $22.5M | $24.7M | $4.0M | $21.4M | $6.8M | $1.1M | $3.4M | $5.8M | $6.5M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $4.3M | $21.4M | $6.7M | $139.0K | $2.0M | $5.8M | $2.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $22.5M | $4.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $327.3K | $149.2K | $69.5K | $1.1M | $0.00 | $2.8M | $1.6M | $1.1M | $682.0K | $303.0K | $34.0K | |
| Net Change in Cash | -$4.5M | $16.4M | -$222.7K | $693.1K | -$18.0M | $14.4M | -$3.3M | -$9.2M | -$2.9M | -$284.0K | $1.0M |
Dilution Tracker
Shares outstanding grew 11674200.0% over 5 years — significant dilution
Shares Outstanding
0M
5-Year Share Growth
+11674200.0%
Stock Issuance (TTM)
$2.3M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.23 | 57.00 | |
| Change vs Prior % | — | 48.8% | 30.0% | 25.0% | -100.0% | 50.0% | 1466.7% | 106.4% | 83029.9% | 189.6% | 24313.5% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $4.3M | $21.4M | $6.7M | $139.0K | $2.0M | $5.8M | $2.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $327.3K | $149.2K | $69.5K | $1.1M | $0.00 | $2.8M | $1.6M | $1.1M | $682.0K | $303.0K | $34.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | — | — | — | -88.1% | -202.3% | -252.4% | |
| Operating Margin % | — | — | — | — | — | — | — | — | -1312.8% | -575.3% | -563.9% | |
| Net Margin % | — | — | — | — | — | — | — | — | 728.9% | -633.6% | -177.0% | |
| EBITDA Margin % | — | — | — | — | — | — | — | — | -1062.2% | -497.9% | -445.7% | |
| FCF Margin % | — | — | — | — | — | — | — | — | -964.6% | -461.9% | -504.2% | |
| ROE % | -35.9% | -61.4% | 281.0% | 167.9% | 28.5% | -1260.3% | 329.3% | 142.3% | 48.1% | -102.5% | -26.6% | |
| ROA % | -30.5% | -42.3% | -82.9% | -94.3% | -7.3% | -38.6% | -21.4% | -37.2% | 35.7% | -71.5% | -15.4% | |
| ROIC % | -41.4% | -31.6% | -91.7% | -80.4% | -118.4% | -35.7% | -44.0% | -60.3% | -71.6% | -72.7% | -55.0% | |
| R&D / Revenue % | — | — | — | — | — | — | — | — | 840.7% | 180.7% | 132.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 99.2% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -5.5% | 100.0% | 0.0% | 0.0% | -357.2% | |
| Operating Income | -6.5% | -120.1% | -203.1% | -10.1% | 12.7% | 45.5% | -2.5% | 12.3% | 11.0% | 12.7% | |
| Net Income | 8.9% | -316.5% | -136.2% | -34.8% | 95.9% | -855.4% | 53.2% | -12.1% | 173.8% | -273.2% | |
| EPS (Diluted) | 28.9% | -179.9% | -81.7% | -7.9% | 97.0% | -650.2% | 95.4% | 60.0% | 100.1% | -160.0% | |
| Operating Cash Flow | 4.9% | -15.3% | -429.5% | -45.9% | 5.5% | 64.8% | 2.2% | -29.1% | 32.5% | 4.8% | |
| Free Cash Flow | 5.0% | -66.6% | -417.2% | -13.1% | 6.5% | 66.9% | -7.1% | -23.7% | 36.7% | 4.6% | |
| R&D Expense | 27.9% | 128.9% | 245.2% | 3.2% | -27.5% | -81.8% | 119.7% | -9.6% | 6.2% | -57.2% | |
| SG&A Expense | 22.3% | 31.5% | -1.7% | 104.0% | 66.9% | 58.2% | -28.7% | -14.9% | -43.9% | -0.2% | |
| Total Assets | -26.3% | 200.4% | 20.5% | 18.4% | -47.2% | 80.9% | -15.5% | -35.4% | -23.0% | -13.5% | |
| Book Value / Share | -39.7% | 63.4% | -139.7% | -80.6% | -70962.8% | 117.0% | -113.4% | -25.3% | 100.3% | -72.0% | |
| Debt | 0.0% | 0.0% | 0.0% | 50.7% | -45.0% | 39.9% | -26.3% | -4.6% | -89.9% | 8.7% | |
| Diluted Shares | 28.0% | 48.8% | 30.0% | 25.0% | -100.0% | 27.4% | 1235.7% | 107.2% | 82465.3% | 189.6% |
Valuation
P/E (TTM)At Loss
P/S0.15
P/B2.14
10Y Low / Med / High0.01 / 0.27 / 1.70
EV/EBITDAAt Loss
EV/Revenue0.64
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$98.25
Tangible Book / Share
$0.21
Cash / Share
$0.05
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.00 | -0.00 | -0.00 | 0.56 | -0.20 | -0.00 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.11 | 1.27 | 0.15 | |
| P/B Ratio | 1.70 | 1.67 | -3.73 | -4.03 | -0.00 | 0.01 | -0.01 | -0.00 | 0.27 | 0.21 | 2.14 | |
| EV/EBITDA | -2.47 | -0.96 | -1.76 | -4.18 | -0.94 | -1.15 | -1.43 | -7.18 | -0.40 | -0.35 | -0.14 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.29 | 1.73 | 0.64 |
Analyst Estimates & Quality
Altman Z-Score
-11.55
Distress
Piotroski F-Score
2
Weak
Revenue Segments
By Product
| Segment | 2024 |
|---|---|
| License | $100.0K |